Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Translational Drug Development Inc.

Division of Translational Genomics Research Institute
www.td2inc.com

Latest From LG Life Sciences Ltd.

Humira's Inevitable Decline: What's Waiting In The Wings?

There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.

Pricing Strategies Biosimilars

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.

Europe Drug Review

Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring

Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.

Biosimilars Research & Development

LG Restructuring Ups Group Emphasis On ‘Red Biotech’

LG's decision to merge its biopharma affiliate LG Life Sciences with the group's main cash cow, LG Chem, signals a focus on "red biotech" and a desire to keep up with other major South Korean conglomerates such as Samsung that are building their biopharma businesses. LG plans to sharply hike sector R&D and capital investments to position the combined operation as a future growth engine.

South Korea Commercial
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register